Shantha Biotechnics

Shantha Biotechnics Limited
Industry Biotechnology, Vaccines
Founded 1993
Founder Koduru Iswara Varaprasad Reddy
Headquarters Medchal, Hyderabad (India)
Key people
 K. I. Varaprasad Reddy (Chairman)
Harish Iyer (CEO)
Products recombinant DNA vaccines
Parent Sanofi
Website Shanthabiotech.com

Shantha Biotechnics is an Indian biotechnology company based in Hyderabad. It is the first Indian company to develop, manufacture and market recombinant human healthcare products in India. The company is a wholly owned subsidiary of Sanofi group.[1]

History

manufacturing facility of Shantha Biotechnics near the Genome Valley

The genesis of Shantha Biotechnics, Ltd. can be traced back to the initiatives of Dr.K.I.Varaprasad Reddy and Khalil Ahmed. Varaprasad and Ahmed established the company in 1993 to produce cost-effective drugs to reach the common man at an affordable price, while maintaining International standards in quality.[1] The project originated as an R&D outfit at the Osmania University under the industry-university interactive programme in 1993, and later operated out of the Center for Cellular and Molecular Biology until an independent R&D facility was built.

In 2006, the European biotech major Mérieux Alliance bought 60% stake in Shantha Biotechnics at a valuation of $175 million. [2]

In 2009, the vaccine division of French pharmacological company Sanofi Pasteur acquired the stake held by Mérieux Alliance, valuing Shantha Biotech at Euro 550 million (over Rs 3,770 crore).[3]

Over time, Sanofi acquired further stake in Shantha Biotechnics and in 2013, acquired 100% of the company. [4]

Products

Drugs developed by Shantha include SHANVAC-B, SHANFERON, SHANKINASE, SHANPOIETIN, SHANTETRA, SHAN5, SHAN HIB-DPT, SHAN HIB, and SHANTT.

Today, Shantha Biotechnics caters to major international markets including Asia-Pacific, Africa, CIS and Latin America in addition to international organisations like UNICEF and PAHO.

Insuman Cartridges Project

CM K.Chandrashekar Rao (KCR) laid stone foundation for Insuman Cartridges project in Medak district.[5] This project will be executed by Shantha Biotechnics Private limited.

The Main object of the insuman cartridges Project is to produce Insulin at a lower cost and located at Medak district Telangana state.The Project Cost for 460 crore.[6]

See also

Genome Valley

References

  1. 1 2 "Shantha Biotech to launch 5-in-1 pediatric vaccine - CNBC-TV18". Moneycontrol.com. Retrieved 2012-09-28.
  2. ↑ "Sanofi-Aventis Takes Control Of Shantha Biotechnics". VCCircle. Retrieved 2015-09-19.
  3. ↑ Somashekar Mulugu. "Business Line : Companies News : Top level changes at Shantha Biotechnics". Thehindubusinessline.com. Retrieved 2012-09-28.
  4. ↑ "Sanofi infusing $122M to complete buy-out of Shantha Biotech and further expansion". VCCircle. Retrieved 2015-09-19.
  5. ↑ Details: CM KCR lays foundation stone for Insuman Cartridges project in Medak
  6. ↑ Details: Insuman Cartridges Project
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.